Trastuzumab emtansine is approved for HER2-positive breast cancer in metastatic cases previously treated with trastuzumab and a taxane, and for early-stage disease with residual cancer after neoadjuvant taxane- and trastuzumab-based therapy.

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining trastuzumab with the cytotoxic agent DM1. It targets HER2-positive cancer cells, blocks HER2 signaling, and triggers immune-mediated cell death. After binding, it is internalized, releasing DM1 to disrupt microtubules, causing cell cycle arrest and apoptosis while limiting damage to healthy cells.

Trastuzumab emtansine is given as an IV infusion. Treatment is administered in a clinical setting with careful monitoring for infusion reactions.

Trastuzumab emtansine may cause fatigue, nausea, headache, constipation, muscle pain, and increased liver enzymes. Low platelets and anemia can also occur. Serious risks include liver damage, heart problems, interstitial lung disease, and infusion reactions. Regular monitoring of liver function, heart health, and blood counts is recommended during treatment.

Trastuzumab emtansine is contraindicated in patients with known hypersensitivity to the drug or its components. Caution is advised in those with liver or heart conditions, as it may cause serious hepatotoxicity and cardiac toxicity. It can also lead to pulmonary issues like interstitial lung disease, and blood disorders such as thrombocytopenia and anemia. Regular monitoring of liver function, heart function, and blood counts is recommended. Use during pregnancy is not advised due to potential fetal harm, and effective contraception is necessary during and after treatment.

Trastuzumab emtansine is an important targeted treatment for HER2-positive breast cancer, offering effective therapy for both metastatic and early-stage disease. By delivering chemotherapy directly to cancer cells, it improves outcomes with less damage to healthy tissue. However, due to risks like liver, heart, and lung toxicity, monitoring and careful patient selection are essential.

Trastuzumab emtansine is an antibody-drug conjugate that combines the HER2-targeting ability of trastuzumab with the cytotoxic agent DM1. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, T-DM1 selectively delivers the cytotoxic drug to HER2-positive cancer cells, minimizing off-target effects.

Patients require regular monitoring of liver function (LFTs), cardiac function (e.g., LVEF by echocardiogram or MUGA scan), and complete blood counts to detect potential hepatotoxicity, cardiotoxicity, and hematologic toxicity.

Yes, T-DM1 is specifically indicated for patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane. It is effective even in cases where prior HER2 therapy has failed.

Serious adverse effects include hepatotoxicity, cardiac dysfunction, interstitial lung disease/pneumonitis, and severe thrombocytopenia. These can be life-threatening and may require dose modifications or discontinuation.

No, T-DM1 is not recommended during pregnancy due to the risk of fetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 7 months after the last dose. Breastfeeding is also not advised during treatment and for 7 months after the final dose.

T-DM1 is generally used as a monotherapy. Its combination with other agents is not standard and should only be considered within clinical trial settings due to limited data on safety and efficacy.

Resistance mechanisms may include HER2 downregulation, altered intracellular trafficking, or efflux of the DM1 payload. Research is ongoing to overcome these mechanisms and improve treatment outcomes.